Astellas Pharma (Japan)

A Cautionary Note on Regional Consistency Evaluation With Multiple Primary Endpoints in Multiregional Clinical Trials

In multiregional clinical trials (MRCTs), regional consistency probabilities (RCPs) must be evaluated at the trial design stage in addition to the power for the entire trial population. The Japanese Ministry of Health, Labour and Welfare guidance proposes two widely used criteria...